Search
Displaying 451–460 of 790 for “retinitis clinical trial”
-
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
Research NewsThe emerging gene therapy is being designed to more safely reach the fovea
-
Partner News
Acquisition significantly expands Janssen’s eye disease portfolio and strengthens its gene therapy capabilities. Late-stage AMD affects millions of people with no effective treatments currently available .
-
Beacon Stories My Retina Tracker Patient Stories
Allen has always wanted to be known as an artist, first and foremost. His photography hints at the ever-changing nature of people’s lives and their environment, much like his own progression with retinitis pigmentosa (RP).
-
Sue Lives Life to the Fullest and Wants to Help Others Do the Same
Beacon StoriesMeet Sue Sanger. Sue was diagnosed with retinitis pigmentosa (RP) at the age of 29 but has continued to travel, advance in her legal and political career, and more. In the following story, Sue explains, in her own words, all she has accomplished since learning she has RP and why she’s a supporter and member of the Foundation Fighting Blindness Legacy Society.
-
Foundation Joins the Institute for Gene Therapies, a Newly Formed Advocacy Organization
Research NewsIGT to accelerate gene therapy development and patient access
-
Funded Grants and Awards for the past few fiscal years
-
The My Retina Tracker Registry is a research database of people and families affected by inherited retinal degenerative diseases.
-
Disease
X-linked retinoschisis (XLRS) is an inherited retinal diseasing causing vision loss due to splitting of the layers of the retina.
-
Ophthotech to Boost Development of Gene Therapy for Best Disease
Research NewsOphthotech Corporation, a biopharmaceutical company focused on the development of therapies for orphan retinal diseases and age-related macular degeneration, has announced an evolving, commercial partnership with the University of Pennsylvania and University of Florida to develop a gene therapy for Best disease caused by BEST1 mutations.
-
FFB Funding More than $2 Million in New Research
Research NewsSeventy scientists submitted requests for funding.
